
U.S. NUCLEAR REGULATORY COMMISSION

MATERIALS LICENSE

Pursuant to the Atomic Energy Act of 1954, as amended, the Energy Reorganization Act of 1974 (Public Law 93-438), and Title 10, Code of Federal Regulations, Chapter I, Parts 30, 31, 32, 33, 34, 35, 36, 37, 39, 40, 70 and 71, and in reliance on statements and representations heretofore made by the licensee, a license is hereby issued authorizing the licensee to receive, acquire, possess, and transfer byproduct, source, and special nuclear material designated below; to use such material for the purpose(s) and at the place(s) designated below; to deliver or transfer such material to persons authorized to receive it in accordance with the regulations of the applicable Part(s). This license shall be deemed to contain the conditions specified in Section 183 of the Atomic Energy Act of 1954, as amended, and is subject to all applicable rules, regulations, and orders of the Nuclear Regulatory Commission now or hereafter in effect and to any conditions specified below.



NRC FORM 374A	U.S. NUCLEAR REGULATORY COMMISSION		PAGE 2 OF 4 PAGES
	License No.: 06-11734-02	Docket or Reference No.:	
MATERIALS LICENSE		030-01287	
SUPPLEMENTARY SHEET	Amendment No. 74		

CONDITIONS

- 10. Licensed material shall be used or stored at the licensee's facilities located at: 326 Washington Street, Norwich, Connecticut, 06360.
- 11. A. The Radiation Safety Officer (RSO) for this license is Daniel Chiappetta, ME, DABHP
 - B. The Associate Radiation Safety Officers (ARSOs) for this license are Anthony Pacella, M.S., CNMT, ARRT(CT), and Christopher C. Smitherman, M.S., DABR, for 10 CFR 35.100, 10 CFR 35.200, and 10 CFR 35.300.
- 12. Licensed material shall only be used by, or under the supervision of:

Authorized Hears

A. Individuals permitted to work as authorized users in accordance with 10 CFR 35.13 and 10 CFR 35.14.

Material and Lice

B. The following individuals are authorized users for the material and medical uses as indicated:

<u>Authorized Osers</u>	Material and Ose
Felicia Cuomo, M.D.	10 CFR 35.100,10 CFR 35.200
William Daniel Donovan, M.D.	10 CFR 35,100,10 CFR 35,200
Nathaniel D. Dueker, M.D.	10 CFR 35.100,10 CFR 35.200; 10 CFR 35.300 (limited to the oral administration of sodium iodide I-131)
Thomas A. Fay, M. D.	10 CFR 35.100,10 CFR 35.200
Kudrat Gill, M.D.	10 CFR 35.100,10 CFR 35.200
Phillip Kohanski, M.D.	10 CFR 35.100,10 CFR 35.200,10 CFR 35.300
Kyle A. Richards, M.D.	10 CFR 35.100,10 CFR 35.200
Stacy L. Spooner, M.D.	10 CFR 35.100,10 CFR 35.200; 10 CFR 35.300 (limited to the oral administration of sodium iodide I-131 in quantities less than or equal to 33 millicuries)
Michael J. Talarico, M.D.	10 CFR 35.100,10 CFR 35.200

IRC FORM 374A	U.S. NUCLEAR REGULATORY	U.S. NUCLEAR REGULATORY COMMISSION PAGE 3 OF 4 PAGES	
	License No.: 06-11734-02	Docket or Reference No.:	
MATERIALS LICENSE		030-01287	
SUPPLEMENTARY SHEET	Amendment No. 74		
Authorized Users	<u>Material and Use</u>		
Kathryn R. Wagner, M.D.	10 CFR 35.100,10 CFR 35.200 iodide I-131)); 10 CFR 35.300 (limited to the ora	l administration of sodium

13. In addition to the possession limits in Item 8, the licensee shall further restrict the possession of licensed material to quantities below the minimum limit in 10 CFR 30.35(d) for which decommissioning financial assurance is required.



NRC FORM 374A	U.S. NUCLEAR REGULATORY COMM	ISSION	PAGE 4 OF 4 PAGES			
MATERIALS LICENSE SUPPLEMENTARY SHEET	License No.: 06-11734-02	Docket or Reference No.: 030-01287				
	Amendment No. 74					
representations, and procedures contained those statements, representations, and plicense condition does not limit the licens. The U.S. Nuclear Regulatory Commission licensee's application and correspondence regulations. A. Application dated December 8, 2023 B. Letter dated March 14, 2024 [ML240] C. Letter dated October 7, 2024 [ML240] D. Letter dated December 2, 2024 [ML240]	A. Application dated December 8, 2023 [ML24002A856] B. Letter dated March 14, 2024 [ML24080A268] C. Letter dated October 7, 2024 [ML24283A074], excluding Attachment 3 (facility diagram) D. Letter dated December 2, 2024 [ML24341A179]					
	FOR	THE U.S. NUCLEAR REGULATO	ORY COMMISSION			
Date: July 1, 2025		ason vonEhr Region 1				